Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Lakewood-Amedex Biotherapeutics, Inc. (LABT)

0.2000 -0.0373 (-15.72%)
At close: October 30 at 4:00:01 PM EDT
0.1907 -0.0093 (-4.65%)
Pre-Market: 8:13:46 AM EST
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
Total Revenue
0
0
0
0
Operating Expense
7,268.7870
3,772.3700
4,026.8200
8,636.7190
Operating Income
-7,268.7870
-3,772.3700
-4,026.8200
-8,636.7190
Net Non Operating Interest Income Expense
-79.1890
-75.2670
137.5960
350.1220
Other Income Expense
--
--
-966.1810
4.6370
Pretax Income
-7,347.3760
-3,847.6370
-4,855.4050
-8,281.9600
Net Income Common Stockholders
-6,974.7440
-3,847.6370
-4,855.4050
-8,281.9600
Diluted NI Available to Com Stockholders
-6,974.7440
-3,847.6370
-4,855.4050
-8,281.9600
Basic EPS
-3.22
-2.76
-6.94
-11.84
Diluted EPS
-3.22
-2.76
-6.94
-11.84
Basic Average Shares
2,169.1990
1,393.5640
699.5460
699.5460
Diluted Average Shares
2,169.1990
1,393.5640
699.5460
699.5460
Total Operating Income as Reported
-7,268.7870
-3,772.3700
-4,026.8200
-8,636.7190
Total Expenses
7,268.7870
3,772.3700
4,026.8200
8,636.7190
Net Income from Continuing & Discontinued Operation
-7,347.3760
-3,847.6370
-4,855.4050
-8,281.9600
Normalized Income
-7,347.3760
-3,847.6370
-3,812.2240
-8,281.9600
Interest Income
45.2800
25.6140
142.5960
360.1220
Interest Expense
124.4690
100.8810
5
10
Net Interest Income
-79.1890
-75.2670
137.5960
350.1220
EBIT
-7,222.9070
-3,746.7560
-4,850.4050
-8,271.9600
EBITDA
-7,101.3370
-3,626.7800
-4,731.8110
-8,150.9750
Reconciled Depreciation
121.5700
119.9760
118.5940
120.9850
Net Income from Continuing Operation Net Minority Interest
-7,347.3760
-3,847.6370
-4,855.4050
-8,281.9600
Total Unusual Items Excluding Goodwill
0
0
-1,043.1810
0
Total Unusual Items
0
0
-1,043.1810
0
Normalized EBITDA
-7,101.3370
-3,626.7800
-3,688.6300
-8,150.9750
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
12/31/2023 - 4/23/2026

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: